Showing superiority to existing therapies would support Al's contention that Afrezza would qualify as a megablockbuster. I might have to try to break my promise to myself and buy some more shares at or below the current level.

I have no way to determine the share price impact but positioning Afrezza for early onset diabetes treatment with superior results means it becomes the new gold standard in diabetes treatment. If it does in fact slow down the progression of the disease and is in use universally all of the projections for share price I have seen are low.

Imagine having a $1 billion invested personally and knowing you are being held back by everyone who stands to lose market share. Pardon the pun but that might be the definition of a bitter pill.